Follow-Up Often Delayed After High-Risk Findings on Lung Cancer Screening
FRIDAY, May 20, 2022 -- Nearly half of lung cancer screening exams with high-risk Lung-RADS findings result in delays in care, according to a study presented at the American Thoracic Society 2022 International Conference, held from May 13 to 18 in San Francisco.
Alwiya Ahmed, M.D., from University of Washington School of Medicine in Seattle, and colleagues examined delays in follow-up after high-risk computed tomography findings that may result in lung cancer diagnosis. The analysis included 397 patients who underwent baseline and annual lung cancer screening (2012 through January 2021) with findings standardized as Lung-RADS 3, 4A, 4B, or 4X.
The researchers found that 464 exams had high-risk findings. Ultimately, 59 patients (15 percent) were diagnosed with lung cancer. In nearly half of high-risk exams (47 percent), there was a delay in follow-up, including 58 percent for Lung-RADS3, 35 percent for Lung-RADS4A, and 37 percent for Lung-RADS4B/4X. For all participants with delayed follow-up, median delay time was 91 days, including 181 days for Lung-RADS3, 68 days for Lung-RADS4A, and 32 days for Lung-RADS4B/4X. Current smoking was associated with higher levels of delay overall, independent of Lung-RADS.
"It is disconcerting to see that among those screened who have abnormal findings, there is a significant delay in recommended follow-up," Ahmed said in a statement. "Interventions are needed at both the provider and patient levels to ensure that high-risk patients receive adequate follow-up."
© 2022 HealthDay. All rights reserved.
Posted May 2022
Read this next
FRIDAY, May 20, 2020 -- From 1999 to 2019, the overall cancer death rate decreased significantly among Black men and women, but in 2019, cancer death rates were still highest for...
FRIDAY, May 20, 2022 -- A perioperative medication-related clinical decision support (CDS) software prototype may reduce the time taken to complete tasks, according to a study...
THURSDAY, May 19, 2022 -- The Pfizer-BioNTech COVID-19 vaccine contributed to substantial public health impact and vaccine-preventable cost savings in the first year of its U.S...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.